Cadherin-17: A potential biomarker for early detection in pancreatic adenocarcinoma

Table 1 Demographic characteristics of pancreatic cancer patients and healthy controls included in the tissue study cohort, n (%)

Variables	Pancreatic cancer patients (n = 25)	Healthy controls (n = 22)
Gender
Male	12 (48)	13 (59)
Female	13 (52)	9 (41)
Age, median (range)	65 (35-75)	35 (1-50)
Smoking history
Non-smoker	17 (68)
Ex-smoker	3 (12)
Smoker	2 (8)
Unknown	3 (12)	22 (100)
Histology
Adenocarcinoma	14 (56)
Ductal adenocarcinoma	10 (40)
Mucinous adenocarcinoma	1 (4)
Differentiation
Well	0 (0)
Moderately	19 (76)
Poorly	5 (20)
Unknown	1 (4)
Tumor site
Head	19 (76)
Body	2 (8)
Tail	4 (16)
Stage at diagnosis
I	1 (4)
II	19 (76)
III	3 (12)
IV	2 (8)
Lymph node invasion
Yes	24 (96)
No	1 (4)
Metastasis
Yes	13 (52)
No	12 (48)

Table 2 Demographic characteristics of pancreatic cancer patients and healthy controls included in the plasma study cohort, n (%)

Variables	Pancreatic cancer patients (n = 28)	Healthy controls (n = 156)
Gender
Male	11 (39)	61 (40)
Female	17 (61)	95 (60)
Age, median (range)	63 (33-76)	62 (45-83)
Smoking history
Non-smoker	20 (71)	129 (83)
Ex-smoker	5 (18)
Smoker	3 (11)	27 (17)
Stage at diagnosis
I	2 (7)
II	5 (18)
III	2 (7)
IV	19 (68)
Lymph node invasion
Yes	26 (93)
No	2 (7)
Metastasis
Yes	19 (68)
No	9 (32)

Table 3 Plasma expression levels of cadherin 17 and carbohydrate antigen 19-9 in paired pre-treatment and post-treatment specimen, stratified by cancer stage

		Healthy	Pre-treatment		Post-treatment
		Controls	Stage I/II	Stage III/IV	Stage I/II	Stage III/IV
CDH17	No. of samples	156	7	21	7	21
	Median (ng/mL)	1.5	7.1	2.0	4.0	2.4
	Range (ng/mL)	0.1-2.9	1.6-11.2	0.6-11.0	0.8-10.2	0.6-32.4
	Mean (ng/mL)	1.5	6.4	3.5	4.7	5.7
CA19-9	No. of samples	30	7	20	7	20
	Median (U/mL)	43	81	167	21	183
	Range (U/mL)	33-66	0-1858	0-195081	0-5540	0-61185
	Mean (U/mL)	45	471	15581	846	3438